BLB Solicitors - The Leading Chronic Pain & CRPS Solicitors
BLB Solicitors - The Leading Chronic Pain & CRPS Solicitors
  • Home
  • About Us
    • Andrew Atkinson
    • Bruce Dyer
    • Clare Lowes
    • David Gazzard
    • Mark Tawn
    • Richard Lowes
  • Pain Conditions
    • CRPS Compensation
    • Fibromyalgia Solicitors
    • Myofascial Pain Syndrome Compensation Claim
    • Somatic Symptom Disorder Compensation Claim
    • Neuropathic Pain Compensation Claim
    • Functional Neurological Disorder Compensation
    • Chronic Fatigue Syndrome (ME) Compensation Claim
    • Chronic Pain Syndrome Compensation Claim
  • Unhappy With Your Solicitor?
  • Case Studies
    • Testimonials
  • Blog
  • Contact Us

Home » Cochrane Review’s surprising conclusion for medical cannabis

Chronic Pain Apr 22nd, 2018
Cannabis

Cochrane Review’s surprising conclusion for medical cannabis

 

In a number of earlier articles, we have considered the effectiveness of cannabis-based products in the treatment of chronic pain. In light of the largely positive way in which their increasingly greater availability has been received, some surprising conclusions have been reported in a recent Cochrane Review*.

The review examined 16 randomised double-blind controlled studies into “the efficacy, tolerability, and safety of cannabis-based medicines…compared to placebo or conventional drugs for conditions with chronic neuropathic pain in adults.”

The 16 studies investigated in the review involved a total of 1,750 participants and evaluated a variety of cannabis products including herbal cannabis, sprays and tablets. The products used either synthetic or plant-derived ingredients.

In a surprise to many, the reviewers concluded that the effectiveness of cannabis-based products for treating the symptoms of chronic neuropathic pain was not supported by the available evidence. Further, such benefits that were seen were outweighed by the potential for psychiatric and neurological side effects.

In conclusion, the reviewers said “Since relatively few participants achieve a worthwhile response with cannabis-based medicines, decisions to use these medicines may require stopping rules to avoid the unnecessary exposure to harms in the absence of benefit.”

* In their own words: “Cochrane Reviews are systematic reviews of primary research in human health care and health policy, and are internationally recognized as the highest standard in evidence-based health care resources. They investigate the effects of interventions for prevention, treatment, and rehabilitation.”

You may also be interested in the following articles:

Cannabis for chronic pain again in the news

Employment issues for those suffering CRPS and Chronic Pain

Chronic Pain linked to increased risk of Dementia

A beginner’s guide to Mindfulness for CRPS and Chronic Pain

Can symptoms of CRPS be remitted using low-dose Naltrexone?

Richard Lowes
Make an Enquiry

Contact Us

Contact Form

Left Column

Right Column

Centre

 
Sending

Recent Articles

  • Meet your chronic pain solicitor: Andrew Atkinson
  • CRPS on the rise but 62% of the UK have never heard of it
  • New fibromyalgia diagnostic guidelines
  • Could spider venom hold the key to treating chronic pain?
  • Study suggests Botox can prolong the benefit of a nerve block for CRPS

Share this Article

Newsletter Sign-up

* indicates required

Legal Glossary

Find Out More

You may also like...

  • Apr 16th, 2018
    Is flying about to get better for travellers with disabilities?
    Read Article
  • Apr 23rd, 2018
    As opioid prescriptions fall in the US are pain-related deaths on the increase?
    Read Article
View All Related Articles

Get in Touch Today

Contact Form

Left Column

Right Column

Centre

 
Sending

1 Edgar Buildings,
George Street,
Bath, BA1 2DU

01225 462871 01225 445060
Authorised & Regulated by Solicitors Regulation Authority (No. 636644).
©2022 BLB Solicitors  |  Privacy & Terms